Takeda discontinuing in AAV and rare haematology disease markets
Pharmaceutical Technology
APRIL 13, 2023
Significant collaborative R&D programmes that are likely to be affected include Takeda’s partnership with Codexis for AAV-based gene therapy for Fabry disease and Takeda’s $3.6bn dollar deal with Poseida for the development of nonviral in vivo gene therapy programmes for the hereditary bleeding disorder haemophilia A.
Let's personalize your content